Songmao Zheng is currently Vice President of Clinical and Quantitative Pharmacology at Adagene, leading quantitative model-informed drug discovery and development in both preclinical and clinical space since 03/2021. Prior to this role, he was Scientific Director/Group Leader leading numerous biologics programs at Janssen BioTherapeutics, Janssen R&D since 12/2013. He has been extensively involved with preclinical, translational and early clinical PK/TE/PD characterization, and provided scientific and strategic input for biologics across Oncology, Immunology and other therapeutic areas. Songmao obtained his B.S. degree in Biological Sciences from Sichuan University (University of Washington (UW), exchange program) in 2007, then a Ph.D. degree in Pharmaceutical Sciences from UW in 2012, followed by his postdoctoral training at the Center for Pharmacometrics & Systems Pharmacology at the University of Florida (UF). He was an intern at Seattle Genetics in 2010 and an ORISE Fellow at US FDA in 2013. Songmao authored ~30 peer-reviewed publications (accumulative Impact Factor ~180)/book chapters, and presented in over 30 conferences with 6 awards. He is also the co-inventor for ~10 Patents (some pending). Within the ~7 years he was with Janssen, he won 1 Philip B. Hofmann Research Scientist Award (the 2nd highest scientific recognition in Johnson & Johnson), 2 J&J Leadership Awards, 1 Janssen Innovation Leadership Award and ~25 J&J ENCORE/Inspire awards. Songmao is currently Editorial Board member for American Society for Clinical Pharmacology and Therapeutics (ASCPT) Family Journal “Clinical Pharmacology & Therapeutics” and “Clinical and Translational Science”, a Member of Scientific Program Committee of ASCPT, and is Affiliate Associate Professor at the UW and Courtesy Adjunct Assistant Professor at the UF.


Selected Publications

‪Zheng Songmao – ‪Google Scholar